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Friedreich ataxia (FRDA) is an autosomal recessive neurodegenerative disorder with an incidence in the European population of approximately 1 in 50 000' and a carrier prevalence of approximately 1 in 100.'-' The disease usually presents with progressive gait and limb ataxia, absent tendon reflexes, and pyramidal weakness in the legs, as well as loss ofposition and vibration sense, and cardiomyopathy is commonly present.' After initial studies linked the gene to the region 9ql 3-q2 1.1,4 Campuzano et 10 More than 95% of affected alleles have an expansion in the number of GAA triplet repeats in intron 1 of FRDA.5 '1"" Normal alleles contain between six and 36 GAA repeats," and disease causing expanded alleles have been observed in a range from 66-1700 repeats,2 12 with the great majority between 700 and 1200 repeats. Expansions between 40 and 100 repeats have been described as premutation alleles, and can either expand further in one generation into full mutations or can be transmitted as a premutation.' 13 14 An increase in the number of triplet repeats correlates with the clinical severity with the size of the smaller allele being more significant in this regard." 12 Until the finding that an expanded GAA trinucleotide repeat causes FRDA, all other conditions with triplet repeat expansions were autosomal dominant or X linked. '7 Instability of trinucleotide repeat size occurs in all of these disorders. In some, maternal transmission is more likely to lead to the child receiving a significantly larger expansion (myotonic dystrophy (DM), fragile X-A syndrome (FRAXA)). In the autosomal dominant conditions with
CAGn expansions, paternal transmission shows preferential expansion (Huntington's disease (HD), DRPLA, SCA1, SCA7, MJD). '8 19 We have studied the FRDA mutations in 66 Australian patients with FRDA from 45 families and their parents where available. We have identified a male premutation carrier, where sperm studies have provided information about the timing of the expansion process in FRDA. We have also examined the alteration in allele size upon transmission from carrier parents to affected children.
Methods

PATIENTS AND FAMILIES
Patients were ascertained either through response to a request in a support group newsletter or by referral from their neurologist. Thirty-eight of the 42 patients on whom clinical details were available were examined by one of the authors (MBD, RJMG, GAN In contrast, in our study, the sperm DNA of the carrier father with the premutation allele has an expanded allele larger than that seen in his leucocyte DNA and it is present in a relatively tight band. This may indicate that meiotic GAA expansion from a premutation is fairly constant in the size of the expansion generated to the resultant spermatozoa. However, this is still smaller than either of the alleles in his affected son. We propose that a two step instability process exists, one prezygotic during generation of sperm, and a second step occurring postzygotically. We cannot exclude the possibility that some sperm are present with a higher repeat number, which results in the son having an allele with a higher repeat number than is seen in the visible band in his father's sperm DNA study. The occurrence of somatic mosaicism between leucocytes and testes resulting in sperm precursors having a larger expansion than that seen in leucocyte DNA is another possible explanation for these findings.
We found no definite example of an increase in size of GAA repeat size in a father to affected child transmission apart from the premutation case described. In FRDA, data have been published for parent to carrier child transmissions of the GAA repeat and here 8/13 contractions of the maternal allele and 9/9 contractions of the paternal allele was observed.2' A recent report indicates that in FRDA, carrier fathers with an allele towards the smaller end of the full mutation expansion range may transmit an allele which increases in size to their offspring, while the children of those males with larger alleles receive a GAA repeat which is smaller than that of their father.22 This report makes assumptions about parental allele assignment to affected offspring; in our study, if the parental allele was between the sizes of the alleles of the affected child, the transmission was not included in our analysis and we made no assumptions about which allele came from which parent.
Transmission data and sperm DNA analyses for other trinucleotide repeat disorders are of interest in interpreting our data. In FRAXA and DM the size of the trinucleotide repeat expansions are similar to that seen in FRDA. Unlike other trinucleotide repeat disorders, in these three diseases the expansion is not within an exon. In males with full mutation FRAXA, the repeat number in sperm reverts from the fully expanded to the premutation range. Timing of trinucleotide repeat instability is not certain in any trinucleotide repeat disorders. In FRAXA it was thought to occur postzygotically with sparing of the male germline,2" but recent evidence suggests that transition from premutation to full mutation in FRAXA is likely to be prezygotic.26 It is suggested that the finding of only premutation alleles in the sperm of full mutation FRAXA males is because of selection against full mutations in the male germline. 26 The occurrence of postzygotic instability is supported by the finding of mosaicism for expansion size in different tissues in DM27 and FRDA.'5 Our findings support a combination of pre-and postzygotic expansion events.
The discovery that expansion of the trinucleotide GAA in the first intron of FRDA is the major cause of autosomal recessive Friedreich ataxia poses further challenges for understanding the biology of unstable trinucleotide repeats. Many models have been proposed to explain how the trinucleotide repeats can expand or contract. Studies on rare or unusual cases, such as the sperm analysis of the premutation carrier presented here, can indicate more general mechanisms relating to this unusual non-mendelian process.
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